TC BioPharm is an early developer of allogeneic Gamma-Delta T-Cell therapies, initially pioneering their use for the treatment of Acute Myeloid Leukemia (AML). It has become the first company to conduct Phase II clinical studies in AML using Gamma-Delta T Cells.

The company operates from an advanced R&D facility in Motherwell. It has a small team of highly skilled employees, including world-class scientists, supported by a dedicated and experienced leadership team with deep sector experience and strong relationships in the US and Europe.

No immediate redundancies are being made whilst the joint administrators undertake a rapid sale of the business.

Michael Magnay, joint administrator, said: “TC BioPharm is a pioneering, clinical-stage cell therapy company with an experienced and highly skilled team.

“As Joint Administrators, our priority is to run a sale process at pace, and we encourage any parties interested in acquiring the business and assets, which include the intellectual property, to reach out to us as soon as possible.”